
Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review
Description
Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Biocon Ltd (Biocon) is a biopharmaceutical company. It focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes, and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics, and biosimilars, including monoclonal antibodies (MAbs), rh-Insulin, and insulin analogs. The company also provides services, including contract manufacturing, drug licensing, research, development, and manufacturing of small and large molecules for biotechnology and pharmaceutical companies globally. It has a manufacturing facility and R&D center at BioXcell, Malaysia. The company has an operational presence in the UK, Ireland, the US, Switzerland, the UAE, and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.
Biocon Ltd Key Recent Developments
May 08,2025: Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%
Jan 30,2025: Biocon Announces Results for Fiscal Q3 Ended December 31, 2024
Dec 24,2024: Biocon Receives EIR with VAI Status from US FDA for Bengaluru API Facility Site-1
Dec 11,2024: Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Biocon Ltd (Biocon) is a biopharmaceutical company. It focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes, and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics, and biosimilars, including monoclonal antibodies (MAbs), rh-Insulin, and insulin analogs. The company also provides services, including contract manufacturing, drug licensing, research, development, and manufacturing of small and large molecules for biotechnology and pharmaceutical companies globally. It has a manufacturing facility and R&D center at BioXcell, Malaysia. The company has an operational presence in the UK, Ireland, the US, Switzerland, the UAE, and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.
Biocon Ltd Key Recent Developments
May 08,2025: Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%
Jan 30,2025: Biocon Announces Results for Fiscal Q3 Ended December 31, 2024
Dec 24,2024: Biocon Receives EIR with VAI Status from US FDA for Bengaluru API Facility Site-1
Dec 11,2024: Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
72 Pages
- Section 1 - About the Company
- Biocon Ltd - Key Facts
- Biocon Ltd - Key Employees
- Biocon Ltd - Key Employee Biographies
- Biocon Ltd - Major Products and Services
- Biocon Ltd - History
- Biocon Ltd - Company Statement
- Biocon Ltd - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Section 2 – Company Analysis
- Company Overview
- Biocon Ltd - Business Description
- Business Segment: Biosimilars
- Overview
- Performance
- Business Segment: Generics
- Overview
- Performance
- Business Segment: Research Services
- Overview
- Performance
- Geographical Segment: European Union (including Ireland)
- Performance
- Geographical Segment: India
- Performance
- Geographical Segment: Rest of the World
- Performance
- Geographical Segment: United States of America
- Performance
- R&D Overview
- Biocon Ltd - Corporate Strategy
- Biocon Ltd - SWOT Analysis
- SWOT Analysis - Overview
- Biocon Ltd - Strengths
- Biocon Ltd - Weaknesses
- Biocon Ltd - Opportunities
- Biocon Ltd - Threats
- Biocon Ltd - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences, Power Financial Deals and Alliances
- Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Biocon Ltd, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- May 08, 2025: Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15% EBITDA at Rs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153%
- Jan 30, 2025: Biocon Announces Results for Fiscal Q3 Ended December 31, 2024
- Dec 24, 2024: Biocon Receives EIR with VAI Status from US FDA for Bengaluru API Facility Site-1
- Dec 11, 2024: Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence
- Dec 07, 2024: Biocon Announces Notification to Stock Exchanges
- Sep 21, 2024: Biocon : US FDA Inspection of API facility, Located at Bengaluru, Karnataka
- Aug 08, 2024: Biocon Q1FY25 Revenue up 30% at Rs 4,567 Cr EBITDA up 117% at Rs 1,755 Cr Net Profit at Rs 660 Cr
- Aug 06, 2024: Biocon Receives USFDA Establishment Inspection Report With Voluntary Action Indicated For Visakhapatnam Facility
- Jun 22, 2024: Biocon : Notification to Stock Exchanges
- May 16, 2024: Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit at Rs 144 Cr
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Biocon Ltd, Key Facts
- Biocon Ltd, Key Employees
- Biocon Ltd, Key Employee Biographies
- Biocon Ltd, Major Products and Services
- Biocon Ltd, History
- Biocon Ltd, Other Locations
- Biocon Ltd, Subsidiaries
- Biocon Ltd, Joint Venture
- Biocon Ltd, Key Competitors
- Biocon Ltd, Ratios based on current share price
- Biocon Ltd, Annual Ratios
- Biocon Ltd, Annual Ratios (Cont...1)
- Biocon Ltd, Annual Ratios (Cont...2)
- Biocon Ltd, Interim Ratios
- Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Biocon Ltd, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- List of Figures
- Biocon Ltd, Performance Chart (2021 - 2025)
- Biocon Ltd, Ratio Charts
- Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2019 to YTD 2025
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.